Koers Evotec SE Other OTC
Aandelen
EVTCY
US30050E1055
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 882 mln. 956 mln. | Omzet 2025 * | 1,03 mld. 1,12 mld. | Marktkapitalisatie | 1,63 mld. 1,77 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -34 mln. -36,87 mln. | Nettowinst (verlies) 2025 * | 31 mln. 33,62 mln. | EV/omzet 2024 * | 2,16 x |
Nettoschuld 2024 * | 278 mln. 301 mln. | Nettoschuld 2025 * | 235 mln. 255 mln. | EV/omzet 2025 * | 1,8 x |
K/w-verhouding 2024 * |
-39,5
x | K/w-verhouding 2025 * |
35
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,64% |
Recentste transcriptie over Evotec SE
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19-06-19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 07-02-23 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 01-05-12 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19-06-19 |
Roland Sackers
BRD | Director/Board Member | 56 | 19-06-19 |
Chairman | 63 | 17-06-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+64,92% | 62,86 mld. | |
-1,85% | 41,38 mld. | |
+45,55% | 40,38 mld. | |
-8,93% | 27,64 mld. | |
+13,05% | 26,46 mld. | |
-21,96% | 18,9 mld. | |
+4,21% | 12,67 mld. | |
+25,74% | 12,27 mld. | |
+27,42% | 12,07 mld. |